Breaking News:

Glenmark gets tentative nod from USFDA for Fingolimod capsules

NEW DELHI, Mar 20:  Drug firm Glenmark Pharmaceuticals USA today said it has got tentative approval from the United States Food and Drug Administration (USFDA) for Fingolimod capsules.
These capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.
“Glenmark Pharmaceuticals USA has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Novartis Pharmaceuticals Corp,” Glenmark said in a BSE filing.
As per IMS Health sales data for the 12 month period ended January 2017, Gilenya capsules 0.5 mg had annual sales of approximately USD 2.03 billion, it added.
(PTI)

related-video

Download Daily Excelsior Apps Now:

google-play-store-badgeappstore_button

Share With
This entry was posted in Business. Bookmark the permalink.

More Related News

Markets

NASDAQ5817.69  chart-3.95
S&P 5002345.96  chart-2.49
INFY15.71  chart+0.06
GCG12.CMXN/A  chartN/A
^NSEBANKN/A  chartN/A
MSFT64.87  chart-0.16
VMW91.14  chart-0.11
PFE34.29  chart-0.18
Scroll to Top